Recent Updates
Recently added Catalysts
ALT

Altimmune to Present at Upcoming Investor and Scientific Conferences

Key Takeaway: GAITHERSBURG, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be presenting virtually at the following conferences: Piper Sandler 33rd Annual Virt
Price reaction · baseline $10.55 (2021-11-19 close) · clean, no other ALT news in the window
day 0 close · peak
-3.3%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+22%
120-day peak, hindsight
Typical move
10.2%
average across 8 past catalysts
Cash runway
~64 mo
Minimal dilution risk
Lead asset
ALT-801
Phase 2 · Obesity/Overweight

Full Press Release Details

GAITHERSBURG, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be presenting virtually at the following conferences:
Piper Sandler 33rd Annual Virtual Healthcare Conference
November 29-December 2, 2021
Webcast available now
5th Annual NASH Summit 2021
9:00 am Eastern Time
4th Annual Evercore ISI HealthCONx Conference
10:55 am Eastern Time
Presentation materials, including webcast links to the Piper Sandler and Evercore ISI presentations, will be accessible on the Events section of the Altimmune website.
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (pemvidutide), and chronic hepatitis B (HepTcell™). For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Altimmune Investor & Media Contact:
Last updated: Nov 22, 2021